Other Clinical Trial - CB1 Receptor PET Imaging Reveals Gender Differences

Status Terminated

Clinical Trial Summary

The objective of the proposed translational study is to test a model, based upon basic science studies, exploring multisystem impairments in PTSD including endocannabinoid (eCB) and glucocorticoids in the modulation of fear memories by examining the cannabinoid type 1 (CB1) receptor in a PTSD fear circuit as well as glucocorticoid function. The investigators propose that impaired eCB signaling in PTSD resulting in the maladaptive neurobehavioral response to the stressor is associated with an upregulation of the CB1 receptors and insufficient glucocorticoid signaling.

Clinical Trial Description

The eCB - anandamide and 2-arachidonoylglycerol (2-AG) - and their attending cannabinoid (CB) receptors which are found in high densities in a fear circuitry involving the amygdala, hippocampus, the anterior cingulate cortex and prefrontal cortex serve important functions in the regulation of stress-coping behaviors. Besides eCB regulation there is strong evidence from ongoing research of the investigators group and others suggesting an important role for glucocorticoid signaling as an endpoint of the biochemical sequelae initiated by stressful or aversive stimuli. One of the long-term research goals of our lab is to understand such functions and determine their relevance to the pathogenesis of PTSD and to provide a more integrative view on neurobiological mechanisms that are involved in the regulation of the neuroadaptive response to stress. The objective of the proposed translational study is to test a model, based upon basic science studies, exploring multisystem impairments in PTSD including eCB and glucocorticoids in the modulation of fear memories by examining the CB1 receptor in a PTSD fear circuit as well as glucocorticoid function. The investigators propose that impaired eCB signaling in PTSD resulting in the maladaptive neurobehavioral response to the stressor is associated with an upregulation of the CB1 receptors and insufficient glucocorticoid signaling. ;

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

Post-traumatic Stress Disorder (PTSD)
Stress Disorders, Post-Traumatic
Stress Disorders, Traumatic

Clinical Trial Details

NCT number	NCT02237677
Study type	Observational
Source	New York University School of Medicine
Contact
Status	Terminated
Phase	N/A
Start date	June 2012
Completion date	March 2016

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT05189977` - A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline	Phase 1
Completed	`NCT01806168` - rTMS in the Treatment of PTSD	N/A
Not yet recruiting	`NCT06194851` - Examining Intranasal Oxytocin Augmentation of Brief Couples Therapy for Veterans With PTSD	Phase 2
Completed	`NCT02187224` - Progesterone Effect on Individuals Diagnoses With AD and PTSD.	Phase 2/Phase 3
Completed	`NCT02549508` - Comparison Study Using APAP With and Without SensAwake in Patients With OSA and PTSD	N/A
Completed	`NCT02012738` - Treatment of Trauma and Violence in the Townships of South Africa	N/A
Not yet recruiting	`NCT01940549` - Transcranial Direct Current Stimulation (tDCS) Enhancement of Trauma-focused Therapy for Posttraumatic Stress Disorder	N/A
Not yet recruiting	`NCT06419959` - NightWare and Cardiovascular Health in Veterans With PTSD	N/A
Terminated	`NCT03209882` - Transcranial Infrared Laser Stimulation (TILS) of Prefrontal Cognition in Post-traumatic Stress Disorder (PTSD)	N/A
Completed	`NCT04891614` - The PRISM Pilot Trial for Post-Traumatic Stress Disorder	N/A
Recruiting	`NCT05407337` - The Effect of Narrative Exposure Therapy Intervention on Post-traumatic Stress Dissorder and Personal Recovery in Refugees and Asylum Seekers of Sindiane Programme	N/A
Completed	`NCT02030522` - Prospective Cohort Study of Accelerated Resolution Therapy (ART) for Treatment of Military Psychological Trauma	N/A
Completed	`NCT01729325` - Prevention of Post-Traumatic Stress Disorder in Soldiers	Phase 2
Completed	`NCT02053532` - Functional Brain Imaging in PTSD	N/A
Not yet recruiting	`NCT02598024` - Treating Earthquake in Nepal Trauma (TENT) Trial 2016	N/A
Terminated	`NCT02237703` - Kappa Opioid Receptor Imaging in Post-traumatic Stress Disorder (PTSD)	N/A
Withdrawn	`NCT02356861` - LED Light Therapy to Improve Cognitive & Psychosocial Function in TBI-PTSD Veterans	N/A
Not yet recruiting	`NCT05974631` - Evaluating Treatments for Suicidal Veterans With PTSD	N/A
Not yet recruiting	`NCT06288594` - TraumaRelief App: A Pilot RCT Assessing Feasibility and Acceptability	N/A
Completed	`NCT01847469` - Zonisamide in Addition to E-CPT-C for Veterans With PTSD and Comorbid Alcohol Dependence	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

CB1 Receptor PET Imaging Reveals Gender Differences in PTSD

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms